Cerasomal doxorubicin with long-term storage stability and controllable sustained release

Yushen Jin, Xiuli Yue, Qingyuan Zhang, Xiaoyi Wu, Zhong Cao, Zhifei Dai

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Liposomal nanohybrid cerasomes display a remarkable ability to maintain their size and retain encapsulated doxorubicin (DOX) over a period of 90 days under storage conditions in solution compared with liposomes and liposils. Cerasomes retained 92.1 ± 2.9% of the drug payload after 90 days storage, much more than liposomes (35.2 ± 2.5%) and liposils (53.2 ± 5.5%). Under physiologically relevant conditions cerasomes exhibit a low initial burst in the first 5 h and subsequent sustained release of DOX over the next 150 h. Moreover, the magnitude of the initial burst and the rate of sustained release of DOX from cerasomes can be modulated by incorporating dipalmitoylphosphatidylglycerol (DPPG) in the cerasome structure and altering the ratios of the cerasome-forming lipid and phospholipids. Consequently, a wide range of release profiles can be achieved by altering the vesicle composition. Finally, human ovarian cancer cells are effectively killed by DOX released from cerasomes. Together these results suggest that cerasomes may be a promising drug delivery system for the long-term storage and controllable sustained release of the anticancer drug DOX.

Original languageEnglish (US)
Pages (from-to)3372-3380
Number of pages9
JournalActa Biomaterialia
Volume8
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Liposomes
Doxorubicin
Phospholipids
Lipids
Cells
Chemical analysis
Drug Delivery Systems
Pharmaceutical Preparations
Ovarian Neoplasms

Keywords

  • Cerasome
  • Controlled release
  • Doxorubicin
  • Storage stability
  • Sustained release

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology

Cite this

Cerasomal doxorubicin with long-term storage stability and controllable sustained release. / Jin, Yushen; Yue, Xiuli; Zhang, Qingyuan; Wu, Xiaoyi; Cao, Zhong; Dai, Zhifei.

In: Acta Biomaterialia, Vol. 8, No. 9, 09.2012, p. 3372-3380.

Research output: Contribution to journalArticle

Jin, Yushen ; Yue, Xiuli ; Zhang, Qingyuan ; Wu, Xiaoyi ; Cao, Zhong ; Dai, Zhifei. / Cerasomal doxorubicin with long-term storage stability and controllable sustained release. In: Acta Biomaterialia. 2012 ; Vol. 8, No. 9. pp. 3372-3380.
@article{36c6b04e965341b2be0f0b400994bcf3,
title = "Cerasomal doxorubicin with long-term storage stability and controllable sustained release",
abstract = "Liposomal nanohybrid cerasomes display a remarkable ability to maintain their size and retain encapsulated doxorubicin (DOX) over a period of 90 days under storage conditions in solution compared with liposomes and liposils. Cerasomes retained 92.1 ± 2.9{\%} of the drug payload after 90 days storage, much more than liposomes (35.2 ± 2.5{\%}) and liposils (53.2 ± 5.5{\%}). Under physiologically relevant conditions cerasomes exhibit a low initial burst in the first 5 h and subsequent sustained release of DOX over the next 150 h. Moreover, the magnitude of the initial burst and the rate of sustained release of DOX from cerasomes can be modulated by incorporating dipalmitoylphosphatidylglycerol (DPPG) in the cerasome structure and altering the ratios of the cerasome-forming lipid and phospholipids. Consequently, a wide range of release profiles can be achieved by altering the vesicle composition. Finally, human ovarian cancer cells are effectively killed by DOX released from cerasomes. Together these results suggest that cerasomes may be a promising drug delivery system for the long-term storage and controllable sustained release of the anticancer drug DOX.",
keywords = "Cerasome, Controlled release, Doxorubicin, Storage stability, Sustained release",
author = "Yushen Jin and Xiuli Yue and Qingyuan Zhang and Xiaoyi Wu and Zhong Cao and Zhifei Dai",
year = "2012",
month = "9",
doi = "10.1016/j.actbio.2012.05.022",
language = "English (US)",
volume = "8",
pages = "3372--3380",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Cerasomal doxorubicin with long-term storage stability and controllable sustained release

AU - Jin, Yushen

AU - Yue, Xiuli

AU - Zhang, Qingyuan

AU - Wu, Xiaoyi

AU - Cao, Zhong

AU - Dai, Zhifei

PY - 2012/9

Y1 - 2012/9

N2 - Liposomal nanohybrid cerasomes display a remarkable ability to maintain their size and retain encapsulated doxorubicin (DOX) over a period of 90 days under storage conditions in solution compared with liposomes and liposils. Cerasomes retained 92.1 ± 2.9% of the drug payload after 90 days storage, much more than liposomes (35.2 ± 2.5%) and liposils (53.2 ± 5.5%). Under physiologically relevant conditions cerasomes exhibit a low initial burst in the first 5 h and subsequent sustained release of DOX over the next 150 h. Moreover, the magnitude of the initial burst and the rate of sustained release of DOX from cerasomes can be modulated by incorporating dipalmitoylphosphatidylglycerol (DPPG) in the cerasome structure and altering the ratios of the cerasome-forming lipid and phospholipids. Consequently, a wide range of release profiles can be achieved by altering the vesicle composition. Finally, human ovarian cancer cells are effectively killed by DOX released from cerasomes. Together these results suggest that cerasomes may be a promising drug delivery system for the long-term storage and controllable sustained release of the anticancer drug DOX.

AB - Liposomal nanohybrid cerasomes display a remarkable ability to maintain their size and retain encapsulated doxorubicin (DOX) over a period of 90 days under storage conditions in solution compared with liposomes and liposils. Cerasomes retained 92.1 ± 2.9% of the drug payload after 90 days storage, much more than liposomes (35.2 ± 2.5%) and liposils (53.2 ± 5.5%). Under physiologically relevant conditions cerasomes exhibit a low initial burst in the first 5 h and subsequent sustained release of DOX over the next 150 h. Moreover, the magnitude of the initial burst and the rate of sustained release of DOX from cerasomes can be modulated by incorporating dipalmitoylphosphatidylglycerol (DPPG) in the cerasome structure and altering the ratios of the cerasome-forming lipid and phospholipids. Consequently, a wide range of release profiles can be achieved by altering the vesicle composition. Finally, human ovarian cancer cells are effectively killed by DOX released from cerasomes. Together these results suggest that cerasomes may be a promising drug delivery system for the long-term storage and controllable sustained release of the anticancer drug DOX.

KW - Cerasome

KW - Controlled release

KW - Doxorubicin

KW - Storage stability

KW - Sustained release

UR - http://www.scopus.com/inward/record.url?scp=84864418546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864418546&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2012.05.022

DO - 10.1016/j.actbio.2012.05.022

M3 - Article

C2 - 22659275

AN - SCOPUS:84864418546

VL - 8

SP - 3372

EP - 3380

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 9

ER -